Most upside (3 months)

The Most Upside chart above shows the companies potential share price gain (%) (the potential share price increase from the current share to the broker target price)

  Company % change  
  Premier African Minerals 43,100.00  
  Ilika 207.69  
  Condor Gold PLC 203.03  
  Abzena Plc 177.61  
  Benchmark Holdings Plc 155.00  
  Velocys 129.47  
  Avacta Group PLC 122.22  
  IP Group PLC 118.82  
  Circassia Pharmaceuticals Plc 107.14  
  hVIVO Plc 94.81  
  Vernalis PLC 91.67  
  PureTech Health Plc 86.36  
  Hikma Pharmaceuticals PLC 77.46  
  Be Heard Group PLC 69.49  
  Spire Healthcare Group 60.38  

Performance Analysis (6 Months)

The performance analysis chart above provides a detailed breakdown of Buy, Sell and Hold recommendations for the selected bank or stockbroker. To see a full explanation of how to use this chart, please visit the performance analysis explanation page.

Recommendation Summary (3 months)

Numis News

  • IG Group upgraded by Numis

    21 September 2017 | IG Group Holdings
    Numis has upgraded IG Group (LON:IGG) to an add rating (from hold) after the online financial trading company delivered a strong first quarter performance. The broker increased its estimates on...
  • Brokers downgrade Keyword Studios

    19 September 2017 | Keywords Studios
    Numis downgraded its recommendation on Keyword Studios (LON:KWS) to hold from buy following the company's interim results, which it said revealed limited material news since the trading update...
  • SIG downgraded by Numis

    18 August 2017 | SIG
    Numis has downgraded its recommendation on European building products distributor SIG (LON:SHI) to reduce (from hold) beliving the valuation is now up with events relative to its unchanged target...
  • Broker views: Snippets from the UK banking sector

    Equity research analysts at HSBC have upgraded their investment rating on Royal Bank of Scotland (LON:RBS) to hold from reduce saying that, while the valuation is full, they see only modest...
  • Broker views: Drugs and booze

    09 August 2017 | AstraZeneca
    Investec boosted its recommendation on pharmaceutical company AstraZeneca (LON:AZN) and moved to a buy rating (from hold) after updating its model for MYSTIC PFS datapoints, positive Tagrisso trial...

Numis Notes